Dr. Hu Zhuohan, Deputy Director of the Drug Metabolism Committee of the Chinese Pharmacological Society, Member of the New Drug Evaluation Committee of the NMPA, and Professor/Doctoral Supervisor at F

At 9:30 AM on June 9, 2020, Professor Hu, Deputy Director of the Drug Metabolism Committee of the Chinese Pharmacological Society, member of the New Drug Evaluation Committee at the National Medical Products Administration (formerly the State Food and Drug Administration), and doctoral supervisor at Fudan University in Shanghai, led a delegation to visit SBK. Dr. Cen Guodong, President of SBK and a Distinguished Expert under Sichuan’s “Thousand Talents Plan” and Chengdu’s “Rong Piao Plan”, along with the Medical Department Director, warmly welcomed the guests.

During the meeting, Dr. Cen provided an overview of SBK’s background, highlighted his own professional achievements, introduced the expert advisory team, and reviewed the company’s R&D accomplishments, support received, and development plans for 2020–2023. His presentation earned strong praise from Professor Hu.

Dr. Cen emphasized that “Innovation is the very soul of SBK”. We grow through innovation; we persevere through growth; we stay true through perseverance; we embrace our imperfections as part of our authenticity; and within those imperfections, we uncover limitless potential! SBK follows a collaborative research model that “Integrates innovation resources for shared success”, combining diverse assets to create unlimited value from limited resources, achieving mutual benefits while advancing the broader biopharmaceutical industry.

After gaining a thorough understanding of SBK’s operations, Professor Hu engaged in a fruitful exchange of ideas with attendees, providing valuable guidance on several innovative projects and future R&D directions.